Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TBI with CLAG-M or FLAG-Ida before HCT for Relapsed/Refractory Myeloid Malignancies
NCT04375631Phase 1Recruiting
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Dec 2020
- Primary completion
- Feb 2027
- Countries
- 1
01
Overview
Phase 1, open-label trial in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML) and 3 more (2 arms), sponsored by Fred Hutchinson Cancer Center. Primary endpoints: Rate of hematopoietic cell transplantation failure at 200 days and Rate of disease progression at 200 days. Started Dec 2020; status: recruiting.
02
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)mixed phenotype acute leukemia (MPAL)acute leukemia of ambiguous lineage (ALAL)
Beyond the preview
Go deeper on NCT04375631.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04375631.